Anagrelide: Finding new use as an adjuvant therapy in cancer management

Dr Richard Franklin, Anagrelide Project Director at SUDA Pharmaceuticals Ltd, is pioneering a radically new application which would see the platelet-lowering drug anagrelide developed as an oromucosal spray formulation. This has the potential to make the most of its recently discovered ability to block cancer cell-stimulated platelet formation and to inhibit cancer cell migration towards platelet precursors (megakaryocytes) while at […]

Read More…

Thank you for expressing interest in joining our mailing list and community. Below you can select how you’d like us to interact with you and we’ll keep you updated with our latest content.

You can change your preferences or unsubscribe by clicking the unsubscribe link in the footer of any email you receive from us, or by contacting us at audience@researchoutreach.org at any time and if you have any questions about how we handle your data, please review our privacy agreement.

Would you like to learn more about our services?

We use MailChimp as our marketing automation platform. By clicking below to submit this form, you acknowledge that the information you provide will be transferred to MailChimp for processing in accordance with their Privacy Policy and Terms.

Subscribe to our FREE PUBLICATION